On August 11, Cardinal Health rose 3.29% in pre-market trading, trading at $242.6 per share, with turnover of approximately $420,300.

The movement was driven by the company releasing fiscal Q4 results that significantly exceeded expectations, alongside a substantial capital return initiative. Cardinal Health reported Q4 adjusted EPS of $2.91, beating the consensus estimate of $2.42 by approximately 20%. While quarterly revenue of $63.672 billion came in slightly below the $65.029 billion estimate, earnings strength overshadowed the top-line miss.

More critically, the company issued fiscal 2027 forward guidance with adjusted EPS of $12.40 to $12.60, well above the FactSet consensus estimate of $12.08. Simultaneously, the board of directors approved an incremental $5 billion stock repurchase authorization, significantly enhancing the company's overall buyback capacity and providing financial flexibility to actively manage its capital structure. The company also maintained its quarterly dividend at $0.5158 per share. The combination of a substantial earnings beat, above-consensus guidance, and an aggressive buyback program collectively propelled the stock higher in pre-market trading.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)